bioihbjkbjnl/mcl2 huggingface dataset:
Effects of THC on Emotional Memory Retrieval
Condition: Healthy
Study type: Interventional
Phase: Early Phase 1

Summary: 
      The main purpose of this study was to examine the effects of THC on the retrieval of
      emotional and neutral memories in healthy young adults. Secondary experiments included the
      effects of THC on the encoding of object and scene stimuli and a novel working memory task.
    

Detailed description: 
      Here, the investigators aimed to investigate the effects of THC (15 mg) on the retrieval of
      negative, neutral, and positive memories. The study used a placebo-controlled,
      within-subjects, crossover design with 24 participants. In each experimental arm,
      participants attend a session to encode stimuli, a second session 48 hours later in which
      their memories are tested for the stimuli from the first session followed by the encoding of
      object-scene stimuli and a working memory test, and a third session 48 hours later in which
      memory for the object-scene stimuli is tested. In the second session, two hours prior to
      memory testing, THC or placebo is administered. On the first and second sessions subjects
      complete mood questionnaires.
    

Intervention name(s): THC; Placebo oral capsule
Intervention type(s): Drug; Drug
Intervention description(s): A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.; A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
Other intervention name(s): Marinol; Dextrose
Intervention MeSH terms: Dronabinol
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: Half of the participants will receive placebo during the second session in the first experimental arm and THC during the second session in the second experimental arm. The other half of participants will receive THC during the second session in the first experimental arm and placebo during the second session in the second experimental arm.
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
Keywords: THC; adult
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
Condition: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
MeSH terms: Infertility
Study type: Interventional
Phase: Phase 4

Summary: 
      The aim of this prospective, non-randomised, open-label, clinical trial is to compare the
      effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH
      Antagonist-Flexible Protocol on clinical and embryological IVF/ICSI outcomes, and on the
      follicular fluid levels of Placental Growth Factor (PlGF); which is known for his pivotal
      role in the regulation of ovulation, embryo development, and implantation.
    


Intervention name(s): Triptorelin acetate; Cetrorelix; recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin; Human Chorionic Gonadotropin (hCG)
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.; 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.; Dosage adjustment according to the ovarian response.; Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Intervention MeSH terms: Triptorelin Pamoate; Chorionic Gonadotropin; Cetrorelix; Menotropins
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: GnRH Agonist; GnRH Antagonist; Assisted reproduction technique; In Vitro Fertilization; Intracytoplasmic sperm injection; Placental growth factor
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Condition: Refractory Chronic Cough
MeSH terms: Cough
Study type: Interventional
Phase: Phase 2

Summary: 
      Study of the efficacy, safety, and tolerability of serlopitant for the treatment of
      refractory chronic cough
    


Intervention name(s): 5 mg Serlopitant Tablets; Matching Placebo Tablets
Intervention type(s): Drug; Drug
Intervention description(s): Serlopitant Tablets; Placebo Tablets
Other intervention name(s): VPD-737
Intervention MeSH terms: Serlopitant
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Pediatric Ultrasound-guided Dorsal Penile Nerve Block Plus Sedation in Spontaneous Breathing
Condition: Child, Only
MeSH terms: Respiratory Aspiration
Study type: Observational

Summary: 
      One of the most frequent surgical procedures in the pediatric population is circumcision,
      following which postoperative pain could be stressful. Usually, the most common approach is
      combining regional anesthesia techniques such as landmark dorsal penile nerve block (DPNB)
      with general anesthesia (GA). The hypothesis of this study investigates ultrasound-guided
      DPNB plus sedation in spontaneous breathing.
    


Intervention name(s): Ultrasound-guided dorsal penile nerve block
Intervention type(s): Procedure
Intervention description(s): This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
Observational model: Case-Control
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Patients' anthropometric data were collected. Data related to the anesthetic technique,
        pharmacological therapy, vital parameters were registered as well as the time to discharge
        from the operatory room to the post-anesthesia care unit.

        Opioid consumption and nonsteroidal anti-inflammatory drugs during and after surgery were
        noted. Pain and complications immediately after surgery, at 4 and 72 hours after surgery
        were registered.
      
Keywords: dorsal nerve penis block; sedation; spontaneous breathing; circumcision; pediatric surgery; ultrasound guided
Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis
Condition: Submassive Pulmonary Embolism
MeSH terms: Pulmonary Embolism; Embolism
Study type: Observational

Summary: 
      Patients with Submassive Pulmonary Embolism treated with ultra-sound therapy will have an
      improved right ventricular function 72 hours post treatment.
    


Intervention name(s): submassive PA treatment with Ekosonic endo device
Intervention type(s): Other
Intervention description(s): Ultra Sound energy along with tPA to treat submassive pulmonary embolism
Other intervention name(s): Ekosonic Endovascular Device
Observational model: Case-Only
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        All patient presenting to the Emergency Department with submassive pulmonary hypertension
        over the age of 18.
      
Keywords: submassive pulmonary embolism; Ultrasonic energy; Ekosonic Endovascular Device; RV:LV function after Pulmonary Embolism
Evaluation and Optimization of Hearing Devices in 3-D Complex Audio Environments Study 3 (HEAR3D_CE3)
Condition: Ability, Spatial
Study type: Interventional

Summary: 
      A methodical evaluation of novel sound changing principles in CE-labelled Sonova brand
      hearing instruments (e.g. Phonak hearing instruments) is intended to be conducted on hearing
      impaired participants. These sound changing principles are enabled by respective hearing
      instrument technologies and hearing instrument algorithms. The aim of the study is to
      investigate and assess strengths and weaknesses of these novel sound changing principles in
      terms of hearing performance to determine their application in hearing instruments (Phase of
      development). Both, objective laboratory measurements as well as subjective evaluations in
      real life environment will be carried out. This will be a controlled, single blinded and
      randomised active comparator clinical evaluation which will be conducted mono centric at the
      University Hospital of Zürich.
    


Intervention name(s): Effect of several processing on the auditory distance perception
Intervention type(s): Procedure
Intervention description(s): The focus is a comparison of hearing instrument algorithms on the auditory distance perception
Intervention model: Single Group Assignment
Intervention model description: a group of normal hearing and hearing-impaired participants
Masking: None (Open Label)
Primary purpose: Other
Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections
Condition: Healthy
Study type: Interventional

Summary: 
      The aim of the present prospective study is to investigate whether the consumption of certain
      probiotic strains over a six-month winter/spring season would be able to affect the incidence
      and duration of upper respiratory tract infections, in otherwise healthy children as well as
      determining whether a combination of two strains would perform differently from a single
      strain version.
    


Intervention name(s): Placebo; Lactobacillus acidophilus NCFM; Combination of Lactobacillus acidophilus and Bifidobacterium lactis
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): Inert excipient; 1e10 CFU/day; 1x10e10 CFU/day
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Prevention
Keywords: Probiotic; Lactobacillus; NCFM; Bifidobacterium; Healthy children
Management of Peri-implant Mucositis With Ozone Water Jet: a Randomized Clinical Trial.
Condition: Peri-implant Mucositis
MeSH terms: Mucositis
Study type: Interventional

Summary: 
      The aim of this study is to assess if ozonized water can be used for the treatment of
      peri-implant mucositis in patients with dental implants.

      Patients willl undergo professional dental hygiene also with the use of glycine powders, then
      they will be randomly divided into two groups:

        -  Trial Group: irrigation of peri-implant periodontium with mucositis with ozonized water.

        -  Placebo Group: irrigation of peri-implant periodontium with mucositis with water.

      Periodontal indices will be recorded at the baseline, after 1 and 2 months. After 1 and 2
      months, only glycine powders will be performed, together with ozonized water or water
      irrigation and the collection of periodontal indices.
    

Detailed description: 
      The aim of this study is to assess if ozonized water can be used for the treatment of
      peri-implant mucositis in patients with dental implants.

      Patients who respond to eligibility criteria and that will sign the informed consent will
      undergo a professional oral hygiene procedure.

      Patients willl undergo professional dental hygiene also with the use of glycine powders.
      Then, glycine powders air-flow will be administered. Then they will be randomly divided into
      two groups:

        -  Trial Group: irrigation of peri-implant periodontium with mucositis with ozonized water.

        -  Placebo Group: irrigation of peri-implant periodontium with mucositis with water.

      Periodontal indices will be recorded at the baseline, after 1 and 2 months. After 1 and 2
      months, only glycine powder will be performed, together with ozonized water/water irrigation
      and the collection of periodontal indices.
    

Intervention name(s): Ozonized water; Placebo
Intervention type(s): Other; Other
Intervention description(s): Irrigation of dental implants with ozonized water; Irrigation of dental implants with water
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: ozonized water
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Condition: Colitis, Ulcerative
MeSH terms: Colitis; Colitis, Ulcerative; Ulcer
Study type: Interventional
Phase: Phase 3

Summary: 
      This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter
      study will investigate the efficacy and safety of etrolizumab in maintenance of remission in
      participants with moderately to severely active UC who are naive to TNF inhibitors and
      refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.
    


Intervention name(s): Etrolizumab; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Participants will receive 105 mg etrolizumab SC injection Q4W.; Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
Other intervention name(s): RG7413; RO5490261; PRO145223; rhuMAb Beta7
Intervention MeSH terms: Etrolizumab
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites
Condition: Allergic Rhinoconjunctivitis
MeSH terms: Conjunctivitis; Conjunctivitis, Allergic
Study type: Interventional
Phase: Phase 1

Summary: 
      The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy
      (SCIT) with House Dust Mite (HDM) extract in patients with rhinoconjunctivitis with or
      without associated mild asthma and sensitized to HDM. In addition,surrogate efficacy
      parameters will be evaluated: immunoglobulin level changes and skin reactivity.

      It will be recruited 50 patients susceptible to receive SCIT with HDM extract along 5
      participating spanish sites.

      Primary endpoint of the study is to assess the safety and tolerability of subcutaneous
      immunotherapy in depot presentation and quick pattern in patients with rhinoconjunctivitis
      with or without mild asthma sensitized to house dust mites

      Secondary objective is to evaluate the indirect immunotherapy efficacy through the
      measurement of immunoglobulin level changes and cutaneous reactivity
    

Detailed description: 
      The aim of present clinical trial is to go deeper into the safety of the vaccine of mixture
      of DPT and DF (50:50). Although this is the first clinical trial to date to be performed with
      this vaccine, there have been two clinical trials with the same formulation and DPT 100% as
      active ingredient( NºEudraCT: 2009-016277-15 and NºEudraCT: 2011-004583-30). Given that there
      is a remarkable cross-reactivity between the DPT and DF mites, the results of the two
      clinical trials conducted to date with subcutaneous depot vaccine with Dermatophagoides
      pteronyssinus 100% extract mite, are very significant
    

Intervention name(s): Allergovac depot DPT/DF (50:50)
Intervention type(s): Biological
Intervention description(s): Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA
Condition: Knee Osteoarthritis
MeSH terms: Osteoarthritis; Osteoarthritis, Knee
Study type: Interventional

Summary: 
      The primary objective of this study is to evaluate the efficacy of Regenexx SD compared to
      Exercise Therapy at three months. Historical comparison will be made to Total Knee
      Arthroplasty for treatment of knee osteoarthritis at 1 and 2 years.
    

Detailed description: 
      The study is single center, prospective, randomized, controlled trial to include 50 subjects,
      25 treated with Regenexx SD and 25 treated with Exercise Therapy for treatment of knee
      osteoarthritis. Subjects will be enrolled within 60 days prior to Regenexx-SD injection or
      initiation of Exercise Therapy and take part in follow-up visits for two years following
      treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will
      occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post
      injection.

      Subjects in the control, exercise therapy arm, will have the opportunity to cross-over to the
      study treatment arm at or after the 3 month visit and then continue to be followed through 24
      months.

      Subjects will complete the study following the 2 year follow-up visit. They will be withdrawn
      from the study prematurely if a revision occurs.

      The study subjects will be compared to a historical total knee arthroplasty group. Data of
      the TKA group subjects will be reviewed retrospectively after it is retrieved from the
      clinical database. The TKA group will consist of patients who underwent TKA for knee
      osteoarthritis. The inclusion criteria of age and BMI will be applied to these subjects.
    

Intervention name(s): Regenexx SD; Exercise Therapy
Intervention type(s): Procedure; Behavioral
Intervention description(s): stem cell treatment; exercise therapy control
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Osteoarthritis; Knee; Arthritis; TKA; Total Knee Arthroplasty
A Study of RG-012 in Subjects With Alport Syndrome
Condition: Alport Syndrome
MeSH terms: Nephritis, Hereditary; Syndrome
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and
      pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
    

Detailed description: 
      This is a Phase 1, multi-center study of the safety, pharmacodynamics, and pharmacokinetics
      of RG-012 administered to subjects with Alport syndrome. During this open-label study, all
      eligible subjects will receive RG-012. The study consists of two parts (Part A and Part B).
      During Part A, half of the participants will receive a single dose of RG-012 and half will
      receive 4 doses of RG-012 (one dose every other week for 6 weeks). All subjects will undergo
      two renal biopsies, one before and one after receiving RG-012, to assess the effect of RG-012
      on the kidney. After completing Part A, subjects will be able to enter Part B of the study.
      During Part B, all subjects will receive RG-012 every other week for 48 weeks.
    

Intervention name(s): RG012
Intervention type(s): Drug
Intervention description(s): RG012 in 0.3% sodium chloride
Allocation: Non-Randomized
Intervention model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Kidney disease; Nephritis; Hereditary kidney disease; Hereditary nephritis
Efficacy Of PF-05089771 In Treating Postoperative Dental Pain
Condition: Postoperative Dental Pain
MeSH terms: Toothache
Study type: Interventional
Phase: Phase 2

Summary: 
      The objective of this study is to evaluate the overall pain relief of a single dose of
      PF-05089771 against placebo following third molar extraction.
    


Intervention name(s): PF-05089771; Placebo; PF-05089771; Placebo; PF-05089771; Placebo; Ibuprofen; Placebo; Placebo; Placebo
Intervention type(s): Drug; Other; Drug; Other; Drug; Other; Drug; Other; Other; Other
Intervention description(s): A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively; Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively; A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively; Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively; A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively; Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively; 2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively; Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively; Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively; Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
Intervention MeSH terms: Ibuprofen
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Postoperative dental pain
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
Condition: Alcoholism; Smoking
MeSH terms: Alcoholism
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched
      placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in
      reducing drinking and smoking in patients with both nicotine and alcohol dependence.
    

Detailed description: 
      Eligible individuals will be randomly assigned to a 12-week trial of a fixed daily dose of
      either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will
      receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews
      will be conducted 3 and 6 months after treatment to determine smoking and drinking status and
      persistence of any dependence symptoms.
    

Intervention name(s): Naltrexone Tablet and Nicotine Patch; Naltrexone Tablet and Placebo Patch; Placebo Tablet and Nicotine Patch; Placebo Tablet and Placebo Patch
Intervention type(s): Drug; Drug; Drug; Drug
Other intervention name(s): Revia and Nicotrol; Revia; Nicotrol
Intervention MeSH terms: Naltrexone; Nicotine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment